Illumina Stock: Discounted Future or Expensive Present?

Illumina has experienced a notable surge, delivering 92.7% returns over the preceding year. This strong performance has sparked a valuation debate, with differing perspectives emerging from Discounted Cash Flow (DCF) analysis and market multiples.

A DCF model, focused on projected free cash flows, estimates Illumina's intrinsic value at approximately $257.50 per share. This valuation suggests the stock is currently trading at a discount of about 27.1% relative to its recent share price of around $195. The model's projections are supported by Illumina's latest twelve-month free cash flow of approximately $913.9 million.

Conversely, prevailing market multiples present a picture of an expensive stock. Recent optimism around Illumina's sequencing platform recovery and expanding clinical applications supports expectations of higher future cash flows. However, the competitive landscape in next-generation sequencing and potential geopolitical restrictions may temper investor willingness to pay a premium for this anticipated growth.

Broader valuation checks by Simply Wall St indicate a mixed valuation for Illumina, scoring 3 out of 6. This suggests neither a clear bargain nor an outright overvaluation. The core question for investors remains whether the recent substantial share price recovery has already captured the company's fundamental value, leaving insufficient margin for upside.